Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $32.93 million. The enterprise value is $10.70 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025.
Earnings Date | May 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 19.49 million shares outstanding. The number of shares has increased by 44.17% in one year.
Current Share Class | 19.49M |
Shares Outstanding | 19.49M |
Shares Change (YoY) | +44.17% |
Shares Change (QoQ) | +26.36% |
Owned by Insiders (%) | 14.28% |
Owned by Institutions (%) | 9.45% |
Float | 15.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.37 |
P/TBV Ratio | 1.37 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.68
Current Ratio | 10.68 |
Quick Ratio | 8.88 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -280.78% and return on invested capital (ROIC) is -151.98%.
Return on Equity (ROE) | -280.78% |
Return on Assets (ROA) | -91.05% |
Return on Invested Capital (ROIC) | -151.98% |
Return on Capital Employed (ROCE) | -103.86% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.94M |
Employee Count | 15 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.33% in the last 52 weeks. The beta is 1.45, so Annovis Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.45 |
52-Week Price Change | -75.33% |
50-Day Moving Average | 1.56 |
200-Day Moving Average | 5.38 |
Relative Strength Index (RSI) | 56.78 |
Average Volume (20 Days) | 508,923 |
Short Selling Information
The latest short interest is 1.95 million, so 10.02% of the outstanding shares have been sold short.
Short Interest | 1.95M |
Short Previous Month | 2.02M |
Short % of Shares Out | 10.02% |
Short % of Float | 12.43% |
Short Ratio (days to cover) | 4.67 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -25.17M |
Pretax Income | -47.53M |
Net Income | -29.06M |
EBITDA | n/a |
EBIT | -25.17M |
Earnings Per Share (EPS) | -$2.09 |
Full Income Statement Balance Sheet
The company has $22.24 million in cash and n/a in debt, giving a net cash position of $22.24 million or $1.14 per share.
Cash & Cash Equivalents | 22.24M |
Total Debt | n/a |
Net Cash | 22.24M |
Net Cash Per Share | $1.14 |
Equity (Book Value) | 24.05M |
Book Value Per Share | 1.23 |
Working Capital | 24.23M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -22.96M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -44.17% |
Shareholder Yield | -44.17% |
Earnings Yield | -88.24% |
FCF Yield | n/a |
Analyst Forecast
The average price target for Annovis Bio is $40.67, which is 2,306.51% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $40.67 |
Price Target Difference | 2,306.51% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -36.15% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |